The telemedicine service Doctis acquired a controlling stake (51%) in the contract research company Ipharma. The cost of the transaction was not disclosed.

The companies jointly intend to develop a platform for the digitalization of clinical trials (CI) of drugs. It also implies the creation of a mobile application for CI participants. With its help, they will enter data on the body's reactions to the drugs under study. The prototype of the platform is expected to be ready in the middle of next year.

Product cards

Doctis, Ipharma

Doctis's plans to acquire a stake in Ifarma to enter the clinical trials market were reported in November 2021. It was also revealed that the processing of the obtained data, their layout, comparison of research results will be carried out using artificial intelligence.

Original (in Russian)